Your browser doesn't support javascript.
loading
Neutralizing Antibody Levels as a Correlate of Protection Against SARS-CoV-2 Infection: A Modeling Analysis.
Lingas, Guillaume; Planas, Delphine; Péré, Hélène; Porrot, Françoise; Guivel-Benhassine, Florence; Staropoli, Isabelle; Duffy, Darragh; Chapuis, Nicolas; Gobeaux, Camille; Veyer, David; Delaugerre, Constance; Le Goff, Jérôme; Getten, Prunelle; Hadjadj, Jérôme; Bellino, Adèle; Parfait, Béatrice; Treluyer, Jean-Marc; Schwartz, Olivier; Guedj, Jérémie; Kernéis, Solen; Terrier, Benjamin.
  • Lingas G; Université Paris Cité, IAME, INSERM, Paris, France.
  • Planas D; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Péré H; Vaccine Research Institute, Créteil, France.
  • Porrot F; Virology Unit, Microbiology Department, APHP, Hôpital Européen Georges-Pompidou, Paris, France.
  • Guivel-Benhassine F; Université Paris Cité, INSERM UMRS1138 Functional Genomics of Solid Tumors Laboratory, Paris, France.
  • Staropoli I; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Duffy D; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Chapuis N; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Gobeaux C; Translational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • Veyer D; Assistance Publique-Hôpitaux de Paris, Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France.
  • Delaugerre C; Department of Automated Biology, CHU de Cochin, AP-HP, Paris, France.
  • Le Goff J; Virology Unit, Microbiology Department, APHP, Hôpital Européen Georges-Pompidou, Paris, France.
  • Getten P; Université Paris Cité, INSERM UMRS1138 Functional Genomics of Solid Tumors Laboratory, Paris, France.
  • Hadjadj J; Virology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
  • Bellino A; Université Paris Cité, Inserm U944, Biology of Emerging Viruses, Paris, France.
  • Parfait B; Virology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
  • Treluyer JM; Université Paris Cité, Inserm U976, INSIGHT Team, Paris, France.
  • Schwartz O; INSERM UMRS 970, Université Paris Descartes, Paris, France.
  • Guedj J; Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP.CUP, Hôpital Cochin, Paris, France.
  • Kernéis S; URC-CIC Paris Centre Necker/Cochin, AP-HP, Hôpital Cochin, Paris, France.
  • Terrier B; Fédération des Centres de Ressources Biologiques - Plateformes de Ressources Biologiques AP-HP.Centre-Université Paris Cité, Centre de Ressources Biologiques Cochin, Hôpital Cochin, Paris, France.
Clin Pharmacol Ther ; 115(1): 86-94, 2024 01.
Article en En | MEDLINE | ID: mdl-37795693
ABSTRACT
Although anti-severe acute respiratory syndrome-coronavirus 2 antibody kinetics have been described in large populations of vaccinated individuals, we still poorly understand how they evolve during a natural infection and how this impacts viral clearance. For that purpose, we analyzed the kinetics of both viral load and neutralizing antibody levels in a prospective cohort of individuals during acute infection with alpha variant. Using a mathematical model, we show that the progressive increase in neutralizing antibodies leads to a shortening of the half-life of both infected cells and infectious viral particles. We estimated that the neutralizing activity reached 90% of its maximal level within 11 days after symptom onset and could reduce the half-life of both infected cells and circulating virus by a 6-fold factor, thus playing a key role to achieve rapid viral clearance. Using this model, we conducted a simulation study to predict in a more general context the protection conferred by pre-existing neutralization titers, due to either vaccination or prior infection. We predicted that a neutralizing activity, as measured by 50% effective dose > 103 , could reduce by 46% the risk of having viral load detectable by standard polymerase chain reaction assays and by 98% the risk of having viral load above the threshold of infectiousness. Our model shows that neutralizing activity could be used to define correlates of protection against infection and transmission.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article